Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: J Allergy Clin Immunol. 2017 Apr 13;140(4):1043–1053.e8. doi: 10.1016/j.jaci.2017.03.028

Fig 4.

Fig 4

Relationship between percent of MOIT doses that led to moderate-severe (Mod/Severe) symptoms, Gl symptoms, or any symptom excluding oropharyngeal (Symptoms excl. oral) over the course of MOIT and basophil %CD63 expression at milk stimulant concentration 10 μg/mL (%CD63+: Milk 10) measured at the baseline (BL) or M4 visit. Statistically significant p-values are discussed in the text. The gray vertical line at %CD63 expression at baseline illustrates the proposed threshold for greatest treatment difference.